Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as BG9924, LT beta
Baminercept alfa 1 · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | subcutaneous administration of placebo given for 12 weeks |
| One Dose | EXPERIMENTAL | BG9924 - dosage level administered as per Biogen Idec protocol |
| Second Dose | EXPERIMENTAL | BG9924 - dosage level administered as per Biogen Idec protocol |
| Third Dose | EXPERIMENTAL | BG9924 - dosage level administered as per Biogen Idec protocol |
| Fourth Dose | EXPERIMENTAL | BG9924 - dosage level administered as per Biogen Idec protocol |
| Fifth Dose | EXPERIMENTAL | BG9924 - dosage level administered as per Biogen Idec protocol |
| Name | Type | Description |
|---|---|---|
| Baminercept alfa 1 | BIOLOGICAL | experimental - one dose level |
| Placebo | BIOLOGICAL | Placebo comparator |
| Baminercept alfa 2 | BIOLOGICAL | experimental - second dose level |
| Baminercept alfa 3 | BIOLOGICAL | experimental - third dose level |
| Baminercept alfa 4 | BIOLOGICAL | experimental - fourth dose level |
| Baminercept alfa 5 | BIOLOGICAL | experimental - fifth dose level |
| BG9924 | DRUG | - |
Key Inclusion Criteria: * Diagnosis of RA (functional class I - III) * Stable dose of MTX * Inadequate response to at least one conventional DMARD therapy Key Exclusion Criteria: * Serious local infection or systemic infection * History (Hx) of recurrent infections requiring oral or parenteral an...
Top 20 of 31 competitors
Baminercept alfa 1 is an investigational therapy being studied for the treatment of rheumatoid arthritis, an autoimmune condition that causes joint inflammation. It is not yet approved for any indication and remains in clinical development. The Phase 2 trial evaluated its safety and efficacy in adults with rheumatoid arthritis.
Baminercept alfa 1 targets LTA, LTB, and TNFSF14, which are members of the lymphotoxin and tumor necrosis factor superfamilies. By inhibiting these targets, the drug is designed to modulate immune pathways involved in inflammation. This mechanism is being explored for its potential to reduce disease activity in rheumatoid arthritis.
Baminercept alfa 1 is being developed by Biogen Inc., which trades on the Nasdaq under the ticker BIIB. Biogen is a biotechnology company focused on neurological and immunological diseases. The company sponsored the Phase 2 clinical trial of this asset.
Baminercept alfa 1 is in Phase 2 clinical development. The only reported trial was a Phase 2 study that has been completed. There are currently no active trials listed for this drug. It is not approved by the FDA or any regulatory agency for any indication.
Baminercept alfa 1 has been studied in one completed Phase 2 trial, NCT00664716, titled Assessment Of The Safety And Efficacy Of BG9924 In Rheumatoid Arthritis (RA) Participants. The trial enrolled 391 adults with rheumatoid arthritis across Argentina, Brazil, Hungary, Mexico, Poland, Romania, Russia, and the United Kingdom.
Yes, Baminercept alfa 1 is also known as BG9924. The Phase 2 trial for rheumatoid arthritis was conducted under the name BG9924. Both names refer to the same investigational monoclonal antibody developed by Biogen.